<DOC>
	<DOCNO>NCT02290340</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics extend half-life anti-respiratory syncytial virus ( RSV ) monoclonal antibody compare placebo administer healthy preterm infant .</brief_summary>
	<brief_title>A Phase 1b/2a Randomized , Double-Blind , Placebo-controlled , Dose-escalation Study Evaluate Safety , Tolerability , Pharmacokinetics MEDI8897 , Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus , Healthy Preterm Infants</brief_title>
	<detailed_description>This Phase 1b/2a study dose-escalation design begin data collection PK safety child . The population enrol healthy preterm infant bear 32 week 0 day 34 week 6 day gestation would receive RSV prophylaxis base American Academy Pediatrics ( AAP ) local guideline . These subject receive palivizumab , allow placebo comparator group begin collect data incidence rate RSV medically attend low respiratory illness ( MA-LRI ) efficacy . Enrollment plan approximately 20 site USA , Chile , South Africa .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects must meet following criterion : 1 . Healthy infant born 32 week 0 day 34 week 6 day gestational age 2 . Infants enter first RSV season time screen . 3 . Subject 's parent ( ) /legal representative able understand comply requirement protocol judge investigator 4 . Subject 's parent ( ) /legal representative must willing able bring subject study site evaluation respiratory illness accordance protocol Any follow would exclude subject participation study : 1 . Gestational age &lt; 32 week 0 day &gt; 34 week 6 day 2 . Meets AAP local criterion receive commercial palivizumab 3 . Any fever ( ≥ 100.4°F [ ≥ 38.0°C ] , regardless route ) low respiratory illness within 7 day prior randomization 4 . Acute illness ( define presence moderate severe sign symptom ) time randomization 5 . Receipt palivizumab RSV vaccine , include maternal RSV vaccination 6 . Any following laboratory finding blood obtain within 7 day prior study entry : Blood urea nitrogen ( BUN ) creatinine &gt; 1.5 × upper limit normal age Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 1.5 × upper limit normal age Hemoglobin &lt; 9.5 gm/dL White blood cell count &lt; 4,000 cells/mm3 Platelet count &lt; 120,000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Respiratory Syncytial Virus , RSV</keyword>
</DOC>